Novel Biological Therapies for Severe Asthma Endotypes
Severe asthma comprises several heterogeneous phenotypes, underpinned by complex pathomechanisms known as endotypes. The latter are driven by intercellular networks mediated by molecular components which can be targeted by specific monoclonal antibodies. With regard to the biological treatments of e...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/5/1064 |
| _version_ | 1797501373091151872 |
|---|---|
| author | Corrado Pelaia Giulia Pelaia Claudia Crimi Angelantonio Maglio Anna Agnese Stanziola Cecilia Calabrese Rosa Terracciano Federico Longhini Alessandro Vatrella |
| author_facet | Corrado Pelaia Giulia Pelaia Claudia Crimi Angelantonio Maglio Anna Agnese Stanziola Cecilia Calabrese Rosa Terracciano Federico Longhini Alessandro Vatrella |
| author_sort | Corrado Pelaia |
| collection | DOAJ |
| description | Severe asthma comprises several heterogeneous phenotypes, underpinned by complex pathomechanisms known as endotypes. The latter are driven by intercellular networks mediated by molecular components which can be targeted by specific monoclonal antibodies. With regard to the biological treatments of either allergic or non-allergic eosinophilic type 2 asthma, currently available antibodies are directed against immunoglobulins E (IgE), interleukin-5 (IL-5) and its receptor, the receptors of interleukins-4 (IL-4) and 13 (IL-13), as well as thymic stromal lymphopoietin (TSLP) and other alarmins. Among these therapeutic strategies, the best choice should be made according to the phenotypic/endotypic features of each patient with severe asthma, who can thus respond with significant clinical and functional improvements. Conversely, very poor options so far characterize the experimental pipelines referring to the perspective biological management of non-type 2 severe asthma, which thereby needs to be the focus of future thorough research. |
| first_indexed | 2024-03-10T03:17:28Z |
| format | Article |
| id | doaj.art-60fdc8bd9e8b47719d315d17fd62591e |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T03:17:28Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-60fdc8bd9e8b47719d315d17fd62591e2023-11-23T10:10:31ZengMDPI AGBiomedicines2227-90592022-05-01105106410.3390/biomedicines10051064Novel Biological Therapies for Severe Asthma EndotypesCorrado Pelaia0Giulia Pelaia1Claudia Crimi2Angelantonio Maglio3Anna Agnese Stanziola4Cecilia Calabrese5Rosa Terracciano6Federico Longhini7Alessandro Vatrella8Department of Health Sciences, University “Magna Græcia” of Catanzaro, 88100 Catanzaro, ItalyDepartment of Health Sciences, University “Magna Græcia” of Catanzaro, 88100 Catanzaro, ItalyDepartment of Clinical and Experimental Medicine, University of Catania, 95123 Catania, ItalyDepartment of Medicine, Surgery and Dentistry, University of Salerno, 84084 Salerno, ItalyFirst Division of Pneumology, High Speciality Hospital “V. Monaldi” and University “Federico II” of Naples, Medical School, 80131 Naples, ItalyDepartment of Translational Medical Sciences, University of Campania “Luigi Vanvitelli”, 80131 Naples, ItalyDepartment of Experimental and Clinical Medicine, University “Magna Græcia” of Catanzaro, 88100 Catanzaro, ItalyDepartment of Medical and Surgical Sciences, University “Magna Græcia” of Catanzaro, 88100 Catanzaro, ItalyDepartment of Medicine, Surgery and Dentistry, University of Salerno, 84084 Salerno, ItalySevere asthma comprises several heterogeneous phenotypes, underpinned by complex pathomechanisms known as endotypes. The latter are driven by intercellular networks mediated by molecular components which can be targeted by specific monoclonal antibodies. With regard to the biological treatments of either allergic or non-allergic eosinophilic type 2 asthma, currently available antibodies are directed against immunoglobulins E (IgE), interleukin-5 (IL-5) and its receptor, the receptors of interleukins-4 (IL-4) and 13 (IL-13), as well as thymic stromal lymphopoietin (TSLP) and other alarmins. Among these therapeutic strategies, the best choice should be made according to the phenotypic/endotypic features of each patient with severe asthma, who can thus respond with significant clinical and functional improvements. Conversely, very poor options so far characterize the experimental pipelines referring to the perspective biological management of non-type 2 severe asthma, which thereby needs to be the focus of future thorough research.https://www.mdpi.com/2227-9059/10/5/1064type 2 severe asthmamonoclonal antibodiesIgEpro-inflammatory cytokinesalarmins |
| spellingShingle | Corrado Pelaia Giulia Pelaia Claudia Crimi Angelantonio Maglio Anna Agnese Stanziola Cecilia Calabrese Rosa Terracciano Federico Longhini Alessandro Vatrella Novel Biological Therapies for Severe Asthma Endotypes Biomedicines type 2 severe asthma monoclonal antibodies IgE pro-inflammatory cytokines alarmins |
| title | Novel Biological Therapies for Severe Asthma Endotypes |
| title_full | Novel Biological Therapies for Severe Asthma Endotypes |
| title_fullStr | Novel Biological Therapies for Severe Asthma Endotypes |
| title_full_unstemmed | Novel Biological Therapies for Severe Asthma Endotypes |
| title_short | Novel Biological Therapies for Severe Asthma Endotypes |
| title_sort | novel biological therapies for severe asthma endotypes |
| topic | type 2 severe asthma monoclonal antibodies IgE pro-inflammatory cytokines alarmins |
| url | https://www.mdpi.com/2227-9059/10/5/1064 |
| work_keys_str_mv | AT corradopelaia novelbiologicaltherapiesforsevereasthmaendotypes AT giuliapelaia novelbiologicaltherapiesforsevereasthmaendotypes AT claudiacrimi novelbiologicaltherapiesforsevereasthmaendotypes AT angelantoniomaglio novelbiologicaltherapiesforsevereasthmaendotypes AT annaagnesestanziola novelbiologicaltherapiesforsevereasthmaendotypes AT ceciliacalabrese novelbiologicaltherapiesforsevereasthmaendotypes AT rosaterracciano novelbiologicaltherapiesforsevereasthmaendotypes AT federicolonghini novelbiologicaltherapiesforsevereasthmaendotypes AT alessandrovatrella novelbiologicaltherapiesforsevereasthmaendotypes |